Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)

Friday, October 12, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

OSLO, Norway, Oct. 12, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators

will present data and analyses from its non-clinical and clinical studies with Betalutin® (177Lu-lilotomab satetraxetan) at the 32nd Annual Congress of the European Association of Nuclear Medicine (13-17 October 2018, Düsseldorf,
Germany).

The presentations are:

Therapeutic efficacy of 177Lu-lilotomab satetraxetan in non-Hodgkin B-cell Lymphoma is controlled by G2/M cell cycle progression

Authors:  A. Pichard et al. Session: 305 - M2M: Therapy Effects, PreclinicalAbstract No. OP-069 Format: Oral presentation

Date/time: Sunday 14 October, 11:30-12:45 CEST

Tumor Absorbed Dose and Changes in FDG PET Parameters in Non-Hodgkin Lymphoma Patients Treated with 177Lu-lilotomab satetraxetan

Authors: A. Løndalen et al.Session: 608 - Clinical Oncology - Rapid Fire Session: It´s in the Blood! Abstract No. OP-252 Format: Oral presentation

Date/time: Monday 15 October, 08:00-09:30 CEST

Abstracts are available by clicking here clicking here

For further information, please contact:

IR enquiries

Malene BrondbergVP Investor Relations and Corporate Communications Cell: +44-7561-431-762 Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44-207-638-9571 Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/nordic-nanovector/r/nordic-nanovector-presentations-at-the-annual-congress-of-the-european-association-of-nuclear-medici,c2642692

Cision View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-presentations-at-the-annual-congress-of-the-european-association-of-nuclear-medicine-eanm-300730074.html

SOURCE Nordic Nanovector



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store